On March 15, 2023 Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, reported that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, NousCom, MAR 15, 2023, View Source;utm_medium=rss&utm_campaign=nouscom-announces-aacr-2023-late-breaking-presentation-of-translational-phase-1b-data-of-nous-pev-a-personalized-neoantigen-cancer-immunotherapy [SID1234628791]). AACR (Free AACR Whitepaper) will be held in
person in Orlando, FL from 14th to 19th April. Poster Presentation Details:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
• Title: NOUS-PEV, a Personalized Cancer Immunotherapy targeting neoantigens,
induces long lasting, tumor infiltrating memory T cells
• Session Title: Late-Breaking Research: Clinical Research 2
• Date & Time: 18th April 2023, 9:00 AM – 12:30 PM EDT
• Location: Poster Section 35, Poster Board 11
• Poster Number: LB196
• Presenter: Dr. Elisa Scarselli, Chief Scientific Officer at Nouscom
The full abstract will be available on 14th April 2023 at 12pm EDT.